BEIJING, July 27, 2015 (GLOBE NEWSWIRE) -- Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, today announced that it entered into an exclusive license with Lawson Health Research Institute (Lawson) to discover, develop and commercialize products based on annexin A5 for the treatment of sepsis in July 2014, and that by this month it has successfully completed discovery validation work and moved the program into preclinical development. The use of annexin A5 to treat sepsis was discovered by a team led by Dr. Qingping Feng, a scientist at Lawson and Western University.
Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialize in China, Taiwan and Hong Kong, while Lawson retains rights in all other markets. Financial terms were not disclosed.
"Yabao is pleased to collaborate with Lawson, a leading Canadian research institute focused on improving the lives of patients through medical discovery. Yabao is also very pleased that the program has been moving very smoothly, showing great potential as a novel drug candidate for a huge unmet medical need," commented Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co., "This opportunity for Yabao to further develop leading research into innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."
"Our partnership with Yabao is proving to be very productive for progressing annexin A5 into clinical development and we are highly encouraged by the results to date," commented Kirk Brown, Manager, Business Development, Lawson Health Research Institute. "Lawson is committed to the translation of health care discoveries from lab bench to patient bedside. To that end Lawson is pleased to collaborate with Yabao, a leading Chinese pharmaceutical company with strong drug development capabilities, to develop this promising new drug for the treatment of sepsis, one of the leading causes of death globally," commented Dr. David Hill, Scientific Director, Lawson Health Research Institute.
About Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully-integrated development, manufacturing, and commercialization in China. Yabao is recently pursuing strategic development of innovative pharmaceuticals in addition to Yabao's well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has strong capabilities in formulation and API production and meets good manufacturing practice (cGMP) requirements with two manufacturing sites approved by US FDA and European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn
Name: Ms. Weina Liu
Email: [email protected]
About Lawson Health Research Institute
Lawson Health Research Institute is the research institute of London Health Sciences Centre and St. Joseph's Health Care London. Working in partnership with Western University, Lawson Health Research Institute is committed to furthering scientific knowledge to advance health care around the world. www.lawsonresearch.com. Commercialization at Lawson is facilitated by WORLDiscoveries®, a joint venture of Lawson, Western University and Robart's Research Institute, the first Canadian technology transfer venture to open permanent satellite offices in China.